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Abstract
Background: A more severe disease phenotype has been reported in men compared to women in several rheumatic
diseases. However, studies have not conclusively established sex-related clinical features in primary Sjögren’s syndrome
(pSS). In this study, we therefore investigated the clinical presentation of pSS in women and men at diagnosis.
Methods: Incident, treatment naïve patients (n = 199) during a 5-year period in a specified area were prospectively
included and examined for items of classification criteria for pSS as well as extraglandular manifestations (EGM). Serum
was sampled at the time of diagnosis and anti-Ro52/SSA levels were measured by ELISA. Replication of significant
findings was confirmed in an independent cohort of pSS patients (n = 377), and meta-analysis was performed.
Results: An increased frequency of extraglandular manifestations in men was observed and replicated (p = 0.05,
p = 0.0003, and pmeta = 0.002). This related to pulmonary involvement, vasculitis, and lymphadenopathy being more
common in men, for whom a lower age at diagnosis was observed in the exploratory cohort. Additionally, SSA-positive
male patients had significantly higher levels of anti-Ro52 levels than their female counterparts in sera available for
analysis (p = 0.02).
Conclusions: Our analysis of two independent cohorts of incident pSS demonstrates that the presence and number of
EGM are significantly more frequent among men with pSS than women at diagnosis. Importantly, around half of the
male patients presented with more than one EGM at diagnosis, supporting the conclusion that pSS in men represents
a more severe form of disease, regardless of the lower risk for men to develop pSS.
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Background
Primary Sjögren’s syndrome (pSS) is an autoimmune
rheumatic disease in which chronic inflammation results in
progressive destruction of exocrine glands, primarily the
salivary and lacrimal glands, leading to symptoms of
dryness [1]. Extraglandular manifestations (EGM) such as
interstitial lung disease, cutaneous vasculitis, and lymph-
adenopathy are present in a subset of patients characterized
by a more systemic phenotype. As part of their auto-
immune disease, pSS patients have a changed pattern in
B-cell maturation and proliferation, resulting in hypergam-
maglobulinemia and autoantibodies against the antigens
Ro/SSA (Ro52 and Ro60) and La/SSB [1–5]. Recently,
autoantibodies against the Ro52 antigen were shown to
functionally inhibit ubiquitination mediated by the E3 ligase
and to correlate with disease activity [6–8].
As for many autoimmune diseases [9], the majority of
patients with pSS are women, with an estimated female
to male ratio of 9–14 to 1 [9–11]. Differential immune
regulation [12–14], X-chromosome gene dosage effects
[15, 16], sex hormones [17–19], and sex-specific expos-
ure to environmental factors [20, 21] have all been
implicated to contribute to these sex differences. In
addition to the difference in disease susceptibility, the
clinical manifestations of autoimmune diseases can also
differ between the sexes.
Interestingly, more severe forms of disease have been
suggested to develop in male than in female patients for
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several autoimmune disorders. In SLE, males have been
reported to have more severe clinical manifestations
than females [22–27]. The tissue damage caused by the
disease, as measured by the Systemic Lupus Inter-
national Collaborating Clinics/American College of
Rheumatology Damage Index (SDI), is more pronounced
in men [28], and the survival rate for male patients with
SLE is lower than their female counterparts [29]. In
systemic sclerosis, male sex is associated with decreased
survival, higher rates of interstitial lung disease, and
diffuse cutaneous disease [30]. Also in patients affected
by multiple sclerosis (MS), male sex is considered to be
a poor prognostic factor, as it is linked to early disability
and faster disease progression [31].
With regard to pSS, a handful of studies have
addressed the clinical and serological differences be-
tween female and male patients without reaching a clear
consensus; primarily due to differences in classification
criteria, study design, patient sample sizes, and ethnic
heterogeneity [32–39]. Further, the cohorts often repre-
sent small and selected groups of patients. In the present
study, we therefore assessed the clinical and immuno-
logical profile of incident cases of female and male pSS
patients in a population-based cohort to determine if the
clinical and serological presentation of the disease differs
between sexes and replicated the findings in an inde-
pendent cohort.
Methods
Patients
The exploration cohort (n = 199; 186 women and 13
men) was established in a population-based manner and
represents an estimated >95% of patients investigated for
and diagnosed with primary Sjögren’s syndrome within
the defined geographic catchment area (Stockholm
County, Sweden) and time period of 5 years (from 1
January 2007 to 31 December 2011) [10]. The patients
were referred to and diagnosed at the Department of
Rheumatology at the Karolinska University Hospital,
Stockholm, Sweden, and more than 90% of the patients
were examined by the same rheumatologist (MK) [10].
All patients were classified according to the 2002 revised
American–European Consensus Criteria (AECC) [40]
for primary Sjögren’s syndrome, and patients fulfilling
criteria for other rheumatic or autoimmune diseases
such as SLE or rheumatoid arthritis were excluded. The
investigation included questions regarding sicca symp-
toms, Schirmer’s test, unstimulated whole salivary flow
test (USWF), and serological analysis of Ro/SSA and La/
SSB autoantibodies by a clinical immunology routine
laboratory using Line blot (2007–2009) or Bio-Plex
(2010–2011) assays. A salivary gland biopsy was
performed if required for a complete diagnostic investi-
gation. A clinical examination was performed at the time
of diagnosis, evaluating general health and systematically
recording features of pSS according to a protocol focus-
ing on extraglandular manifestations (EGM) [10]. We
defined EGM as typical organ manifestations from our
clinical experience with pSS patients and also required
that they should have been described previously in the
literature. These EGM correspond to those later defined
in the European League Against Rheumatism (EULAR)
Sjögren’s syndrome disease activity index (ESSDAI)
published in 2010 [41]. We regarded the symptoms and
organ manifestations in each individual as EGM of pSS
if no other explanation was present. An abnormal
computer tomography (CT) of the lungs was required
for the diagnosis of interstitial lung disease. Exclusion of
other autoimmune diseases was made based on physical
examination by the rheumatologist, results from blood
samples including immunology testing and if necessary
X-ray and other investigations like skin biopsy and
neurography. A serum sample taken at the time of diag-
nosis was available for 146 patients (female n = 136, male
n = 10). The study was approved by the Regional Ethics
Committee Stockholm North, and all participants gave
written informed consent.
Replication was performed in an incident cohort of
patients with Sjögren’s syndrome (n = 377; 368 women
and 9 men) diagnosed at the Rheumatology Unit,
University Hospital of Pisa, Pisa, Italy, by the same pro-
cedures as described above. The cohort was represented
by patients referred to the Rheumatology Unit mainly
from central Italy for investigation of pSS during an 8-
year period (from 1 January 2007 to 1 January 2015).
Caucasian patients represented >95% of the cases. More
than 90% of the patients were examined by the same
rheumatologist (CB). Similarly to the Swedish cohort, all
patients were classified according to the 2002 revised
American–European Consensus Criteria (AECC). All
patients gave informed consent for all procedures, which
were carried out with local ethics committee approval
(Comitato di Bioetica, University of Pisa).
Anti-Ro52/SSA ELISA
Furthermore, ELISA for anti-Ro52 autoantibodies was
performed as previously described [42–45]. Briefly,
high binding 96-well plates (Nunc) were coated with
1 μg of recombinant full-length Ro52 protein per
well, diluted in carbonate buffer (pH 9.6). Before use,
the plates were blocked with phosphate-buffered sa-
line (PBS)/0.05% Tween/5% milk powder for 2 h.
Sera diluted in Tween-PBS/1% milk powder were
added and incubated for 2 h at room temperature.
Autoantibody binding was detected with an alkaline
phosphatase-conjugated rabbit anti-human IgG anti-
body 1:2000 (Dakopatts), which was incubated for
2 h at room temperature. Finally, binding was
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visualized using phosphatase substrate tablets (Sigma)
and measured at 405 nm absorbance. A high anti-
Ro52 titer serum was used as standard with serial
dilutions for calculation of arbitrary units of antibody
levels.
Statistical analysis
For statistical comparisons of categorical variables
between groups, the Chi-square test for 2 × 2 contin-
gency tables was performed; Fisher’s exact test was
employed if the observed frequency of any given cell
was <5. Numerical variables were analyzed by the
Mann–Whitney U test. The statistical analysis was
done using Prism GraphPad 6. For meta-analyses of
data from the two pSS cohorts, the heterogeneity be-
tween both studies was measured as I2. When I2 was
below 0.5, a fixed effect model was employed; other-
wise, in cases of higher heterogeneity of data, the
random effect model was considered. Meta-analyses
were performed with Review Manager (RevMan) soft-
ware Version 5.3. (Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014). A p value
<0.05 was considered significant.
Results
Basic characteristics and AECC items in female and male
patients at diagnosis of Sjögren’s syndrome
A population-based cohort of incident cases of pSS (n= 199;
93% women and 7% men) (Table 1) was explored for poten-
tial differences in presentation between female and male pa-
tients. Among basic characteristics, we found that male
patients were significantly younger at diagnosis, namely, 46
± 12 years in male patients compared to 56 ± 14 years for fe-
male patients (mean ±95% CI; p= 0.01). Notably, 67% of the
women were diagnosed after the age of 50, which is
commonly used as an approximation for menopause.
The frequency of items included in the 2002 AECC for
Sjögren’s syndrome was assessed. No significant differ-
ences in either subjective or objective ocular and oral
signs were observed between female and male patients
(Table 1). Salivary and lacrimal gland function was
assessed by UWSF and Schirmer’s test, respectively, with
no significant differences in secretory capacities
observed. Approximately, 90% of both women and men
had undergone salivary gland biopsy, with no significant
difference in the frequencies of a positive result (Table 1),
or degree of inflammation as measured by the focus
score (data not shown). In summary, this indicates that
female and male patients fulfill items III, IV, and V of
the diagnostic criteria for pSS in a similar fashion.
Autoantibodies in female and male patients
SSA and SSB autoantibodies in serum were analyzed by
a clinical routine diagnostic laboratory with no apparent
difference in frequency of a positive result between
female and male patients (Table 1). Since autoantibody
levels were not quantified by the clinical laboratory, we
performed a specific anti-SSA/Ro52 ELISA using
purified recombinant antigen and sera taken at the time
of diagnosis to evaluate whether autoantibody levels
differed among SSA-positive female and male patients.
Interestingly, we found that the SSA-positive men
presented with significantly higher levels of anti-Ro52
antibodies than the women (p = 0.02) (Fig. 1), although
the number of sera available for analysis was low
(women n = 61 and men n = 5, respectively).
Differences in extraglandular manifestations among
women and men diagnosed with pSS
Previous studies indicate that approximately 40% of
patients with pSS experience some degree of extra-
glandular involvement [46]. The presence and number
of EGM in our exploratory cohort of pSS patients
were assessed at diagnosis (Table 2). Pulmonary
involvement in terms of interstitial lung disease (p =
0.004), as well as cutaneous vasculitis (p = 0.007),
were significantly more frequent in men. The occur-
rence of other common or specific clinical
Table 1 Basic characteristics and objective pSS classification items
of the patients in the exploratory cohort
Women
n = 186
% (frequency)
Men
n = 13
% (frequency)
p value
Basic characteristics
Sex 93% (186/199) 7% (13/199) <0.0001
Age at diagnosis, years
(mean ± SD)
56 ± 14 46 ± 12 0.01
Item III. Ocular signsa
Schirmer’s test
(≤5 mm in 5 min)
70% (129/185) 77% (10/13) 0.58
Item IV. Histopathologya
Minor salivary gland biopsya
Performed 85% (158/185) 92% (12/13) 0.49
Positive
(focus score ≥1)
95% (149/157) 83% (10/12) 0.10
Item V. Salivary gland involvementa
UWSFb 78% (145/186) 77% (10/13) 0.93
Item VI. Autoantibodiesa
Positive (SSA and/or SSB) 55% (100/183) 54% (7/13) 0.96
SSA positive 53% (97/184) 46% (6/13) 0.65
SSB positive 30% (55/184) 33% (4/12) 0.80
aAccording to the 2002 revised American–European Consensus Group criteria
for Sjögren’s syndrome
bUnstimulated whole salivary flow, ≤1.5 ml in 15 min
Bold values indicate statistically significant findings (p < 0.05)
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manifestations of Sjögren’s syndrome was also investi-
gated, but no significant differences between men and
women were observed (Table 3 ).
We further analyzed whether the frequency and number
of concomitant extraglandular manifestations differed be-
tween the sexes, as a sign of more severe disease. We ob-
served a trend towards more male patients presenting
with at diagnosis (p = 0.10), and interestingly, among those
men that had at least one EGM (EGM+), the number of
concomitant extraglandular manifestations was signifi-
cantly higher than in the female group (p = 0.04) (Table 2).
Replication and meta-analysis in an independent cohort
To validate our observations, replication and meta-
analysis were performed for parameters displaying a
skewed frequency between male and female patients
(Table 4). The cut-off for selecting parameters for
replication and meta-analysis was set at p = 0.25, to
allow investigation of trends that had not reached
statistical significance in the first cohort. Notably,
interstitial lung disease, cutaneous vasculitis, and both
presence of and higher number of concomitant extra-
glandular manifestations were confirmed as parame-
ters more frequently observed in men at diagnosis
with pSS than in women being diagnosed with the
disease (Table 4). Further, the trends observed for
alveolitis, lymphadenopathy, and recurrent fever were
confirmed as significant by the meta-analysis (p = 0.01, p
= 0.004, and p = 0.0008, respectively) (Table 4). The repli-
cation cohort and meta-analysis also confirmed the higher
frequency of EMG in men, as well as more concomitant
EGM in EGM+ men (Table 4).
Discussion
In this study, we provide evidence that there are dif-
ferences, not only in incidence, but also in clinical
presentation between women and men with pSS at
the time of diagnosis. We explored sex-differences in
a population-based cohort of incident pSS and used
an independent cohort to confirm observations. Our
results reveal a more severe disease phenotype in
men at diagnosis. In addition, the immune activity
represented by autoantibodies against the SSA-
component Ro52 showed significantly higher levels of
these specific antibodies in SSA-positive male com-
pared to female patients.
We found that EGM are more common in male than in
female patients at the time of pSS diagnosis. In our
population-based cohort, the number of EGM among
EGM+ patients was significantly higher in male than that
in female patients, which was very close to significant in
the replication cohort. A meta-analysis confirmed that the
presence of EGM as well as number of EGM is more
common in men with pSS. Similar trends have been previ-
ously reported for prevalent pSS, although statistical
significance has been difficult to obtain due to the small
number of men in the studies [32, 38, 47].
In our study, the frequencies of specific EGM also dif-
fered significantly between women and men. Interstitial
lung disease and cutaneous vasculitis were significantly
more common in men in our population-based cohort,
and a similar trend was observed for interstitial lung
disease in the replication cohort, resulting in a signifi-
cant difference in the meta-analysis. Similarly, lymph-
adenopathy and recurrent fever were significantly more
common in the replication cohort while it only shows a
tendency in the exploratory cohort. Alveolitis displayed
a strong tendency in the exploratory cohort which was
confirmed after the meta-analysis, though the observa-
tion should be interpreted with caution considering the
low numbers. A higher frequency of pulmonary involve-
ment in male patients has been suggested by previous
studies [34, 37], though statistical significance was not
reached in these investigations. Also, lymphadenopathy
has been associated with male sex [36, 37, 39]. In all,
similar trends for higher frequencies of specific EGM are
found in male patients. It is important to point out that
no EGM was significantly more frequent in the female
patients in either cohort in our study. In summary, our
Fig. 1 Anti-Ro52 antibody levels in SSA-positive patients with pSS.
Anti-Ro52 levels were analyzed in serum samples from 61 female
and 5 male SSA autoantibody-positive pSS patients. Male patients had
significantly higher anti-Ro52 levels than female patients (p = 0.02,
Mann–Whitney U test)
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data establishes that men present with a more severe
disease phenotype with more EMG at the time of diag-
nosis of pSS.
No major differences were observed for the lacrimal
and salivary gland function between women and men
with pSS in either cohort. The serological investigation
of the pSS patients revealed that SSA-positive men have
significantly higher levels of anti-Ro52 at diagnosis than
women, and of note, the patient with the highest auto-
antibody levels was a man. Although this finding can
help explain the increased severity of the disease in men,
the few sera available for analysis should be noted. Fur-
ther studies with larger sample sizes might be able to
definitely establish a marked serological difference
between female and male patients. Serological investiga-
tions performed in previous studies show considerable
discrepancies between the frequencies of anti-Ro/SSA
positivity among the male patients. Some papers
highlight significant serological differences between the
sexes with a tendency for men to be less frequently sero-
positive [34–36, 38], but the antibody levels in seroposi-
tive individuals are rarely compared. However, Drosos et
al. [36] reported that female patients have higher anti-Ro
levels than males. The different observations may relate
to the time point of serum sampling, as it is possible that
more women develop higher autoantibody levels with
disease progression. The differences between studies
could potentially also depend on the assay used for
Table 2 Frequency of extraglandular manifestations in female and male pSS patients in the exploratory cohort
pSS all
(n = 199)
% (frequency)
Women
(n = 186)
% (frequency)
Men
(n = 13)
% (frequency)
p value
Presence of EGM 30% (53/197) 25% (47/185) 46% (6/13) 0.10
No. of EGM (mean ± SD) 0.34 ± 0.64 0.30 ± 0.57 0.85 ± 1.21 0.05
No. of EGM in EGM+ patients
(mean ± SD)
1.26 ± 0.59 1.19 ± 0.45 1.83 ± 1.17 0.04
Extraglandular manifestationsa
Articular
Arthritis 14% (28/197) 14% (26/184) 15% (2/13) 1.00
Pulmonary
Interstitial lung disease 1% (2/196) 0% (0/183) 15% (2/13) 0.004
Alveolitis 0.5% (1/197) 0% (0/184) 8% (1/13) 0.07
Renal
Interstitial nephritis 0.5% (1/197) 0.5% (1/184) 0% (0/13) 1.00
Cutaneous
Cutaneous vasculitis 4% (7/195) 2% (4/182) 23% (3/13) 0.007
Neurological
Polyneuropathy 4% (8/195) 4% (7/182) 8% (1/13) 0.43
Mononeuritis 0.5% (1/197) 0.5% (1/184) 0% (0/13) 1.00
CNS involvement 1% (2/197) 1% (2/184) 0% (0/13) 1.00
Constitutional
Recurrent fever 7% (14/197) 7% (12/184) 15% (2/13) 0.23
Lymphadenopathy
Enlarged lymph nodes 1% (4/197) 2% (3/184) 8% (1/13) 0.24
Muscular
Myositis 2% (3/197) 0.5% (1/184) 0% (0/13) 1.00
aExtraglandular manifestations evaluated to estimate the EULAR Sjögren’s syndrome disease activity index (ESSDAI)
Bold values indicate statistically significant findings (p < 0.05)
Table 3 Frequency of other common clinical manifestations
of pSS
Women
n = 186
% (frequency)
Men
n = 13
% (frequency)
p value
Raynaud’s phenomenon 21% (38/181) 15% (2/13) 1.00
Major salivary gland
swelling
10% (18/185) 15% (2/13) 0.63
Cryoglobulinemia 0% (0/186) 0% (0/13) –
Lymphoma 0% (0/186) 0% (0/13) –
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autoantibody testing and the presence of Ro60 and Ro52
antigens, respectively. Notably, Ro52 antibodies have
been associated with pulmonary disease, particularly
interstitial lung disease and pulmonary fibrosis [48, 49],
which we also observed more frequently in men from
our cohort.
The strength of our investigation is that the studied
exploration cohort was generated in a population-based
manner representing approximately 95% of all incident
cases in the specific geographical area during the 5-year
period during which the cohort was established [10]. By
this approach, selection bias was avoided. Also, more than
90% of the patients were examined and diagnosed by the
same clinician, diminishing variation in assessment proce-
dures and evaluation [10]. An additional strength of the
study is that an independent cohort of incident pSS is
used to verify observations. Around 90% of patients were
seen by one specific clinician also in this cohort.
Noteworthy, the replication cohort was not population-
based, potentially explaining some of the differences
observed between the cohorts. The catchment and inclu-
sion of patients in the replication cohort might have been
more delayed than in the exploratory cohort, which could
account for higher numbers of EGM. Despite this, men
from the replication cohort still showed a more severe
disease phenotype.
More than nine out of ten patients with pSS are
women, and an inherent weakness of studies of sex-
differences of pSS is thus the smaller number of men in
any given cohort. This is also the main drawback of the
present study, despite including all cases in a densely
populated defined geographical area during a 5-year
period and using a replication cohort.
Conclusions
In conclusion, the clinical data from our two-cohort pSS
study highlights differences in the presentation of the
disease between women and men. Despite the fact that
men are less prone to develop pSS, this study demon-
strates that, at the time of diagnosis, male patients have
a more severe disease than females with more EGMs.
This suggests that the pathogenic mechanisms of pSS
may vary between women and men, and that medical in-
terventions should aim to approach this disease in a sex-
specific manner.
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Table 4 Replication and meta-analysis of manifestations with different frequencies among female and male patients with pSS
Ramírez Sepúlveda et al. Baldini et al. Meta-analysis
Women
(n = 186)
% (frequency)
Men
(n = 13)
% (frequency)
p value Women
(n = 368)
% (frequency)
Men
(n = 9)
% (frequency)
p value p value
Age at diagnosis 56 ± 14 46 ± 12 0.01 51 ± 15 53 ± 13 0.86 0.07
Positive MSG biopsya 95% (149/157) 83% (10/12) 0.10 93% (293/315) 100% (8/8) 0.43 0.30
Presence of EGMb 25% (47/185) 46% (6/13) 0.10 56% (205/368) 100% (9/9) 0.006 0.005
No. of EGMc 0.30 ± 0.57 0.85 ± 1.21 0.05 1.11 ± 1.39 2.89 ± 1.62 0.0003 0.002
No. of EGM in EGM + c 1.19 ± 0.45 1.83 ± 1.17 0.04 1.89 ± 1.16 2.67 ± 1.41 0.06 0.04
Interstitial lung disease 0% (0/183) 15% (2/13) 0.004 9% (32/368) 22% (2/9) 0.19 0.002
Alveolitis 0% (0/184) 8% (1/13) 0.07 2% (6/368) 0% (0/9) 1.00 0.01
Cutaneous vasculitis 2% (4/182) 23% (3/13) 0.007 10% (38/368) 11% (1/9) 1.00 0.03
Lymphadenopathy 2% (3/184) 8% (1/13) 0.24 37% (138/367) 89% (8/9) 0.003 0.004
Recurrent fever 7% (12/184) 15% (2/13) 0.23 18% (66/368) 67% (6/9) 0.002 0.0008
MSG minor salivary gland biopsy
aFocus score ≥1
bExtraglandular manifestations evaluated to estimate the EULAR Sjögren’s syndrome disease activity index (ESSDAI)
c(mean ± SD)
Bold values indicate statistically significant findings (p < 0.05)
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